Anti-Obesity Drugs

Anti-Obesity Drugs

Global Anti-Obesity Drugs Market to Reach $4.8 Billion by 2030
The global market for Anti-Obesity Drugs estimated at US$2.7 Billion in the year 2023, is expected to reach US$4.8 Billion by 2030, growing at a CAGR of 8.7% over the period 2023-2030. Prescription Drugs, one of the segments analyzed in the report, is expected to record 8.5% CAGR and reach US$4.4 Billion by the end of the analysis period. Growth in the OTC Drugs segment is estimated at 10.9% CAGR for the next 7-year period.

The U.S. Market is Estimated at $827.9 Million, While China is Forecast to Grow at 7.9% CAGR
The Anti-Obesity Drugs market in the U.S. is estimated at US$827.9 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$812.2 Million by the year 2030 trailing a CAGR of 7.9% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.9% and 7.1% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 7% CAGR.

What to Expect from the Global Economy in 2024
Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.

Select Competitors (Total 23 Featured) -
  • Eisai Co. Ltd. (Japan)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • GlaxoSmithKline Plc
  • Novo Nordisk A/S (Denmark)
  • Rhythm Pharmaceuticals (US)
  • VIVUS Inc. (US)
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Global Economic Update
Obesity and Overweight Statistics
Recent Market Activity
Obesity - A Prelude
Anti-Obesity Drugs: A Market Characterized by High Unmet Needs
Currently Available Anti-Obesity Medications
Select Currently Available Short-term and Long-term Anti-Obesity Medication
Select Off-Label Drugs for Obesity
Saxenda Commands the AOM Market, Newer Drugs to Provide Impetus to Market Growth
Semaglutide: Highest Potential in the AOM Pipeline
Setbacks of Past Drugs
Positive Road Ahead for Belviq
Relaunch of Xenical
Relaunch of Contrave(r)
Reluctance among Patients, Physicians, and Payers Hurts Market Prospects
New Drug Development - High on the Agenda, Despite the Market Restraints
Anti-Obesity Drugs in Phase-III Clinical Trials: As of July 2018
Anti-Obesity Drugs in Phase-II Clinical Trials: As of July 2018
Anti-Obesity Drugs in Phase-I Clinical Trials: As of July 2018
Diabetes Drug Companies Attempt to Foray into the Anti-Obesity Drugs Space
Competitive Landscape
Novo Nordisk - The Leading Player in the Market
The United States - The Largest Obesity and Anti-Obesity Market
Europe - A Market with Vast Potential
Obesity Creeps Up in Developing Countries
Anti-Obesity Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
F. Hoffmann-La Roche Ltd. (Switzerland)
GlaxoSmithKline Plc. (UK)
Eisai Co., Ltd. (Japan)
Novo Nordisk A/S (Denmark)
Rhythm Pharmaceuticals (USA)
VIVUS, Inc. (USA)
3. MARKET TRENDS & DRIVERS
Alarming Rise in Global Obesity Levels - The Major Growth Factor
Classification of BMI
Rising Incidence of Chronic Diseases Associated with Obesity Drive the Market Expansion
Growing Middle Class Population to Drive the Market Growth
Childhood Obesity - A Market with Unmet Needs
Commercial Weight-Loss Companies Foray into the Market
Online Drug Stores Boost Sales
Barriers to Development of Effective Drugs
Regulatory Additions - A Barrier to Entry?
High Drug Development Costs - A Major Setback
Weight Loss Alternatives - A Market Dampener
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 2: World 7-Year Perspective for Anti-Obesity Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
TABLE 3: World Recent Past, Current & Future Analysis for Prescription Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 4: World 7-Year Perspective for Prescription Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for OTC Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 6: World 7-Year Perspective for OTC Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 7: World Anti-Obesity Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
Anti-Obesity Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 8: USA Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 9: USA 7-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2024 & 2030
CANADA
TABLE 10: Canada Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 11: Canada 7-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2024 & 2030
JAPAN
Anti-Obesity Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 12: Japan Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 13: Japan 7-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2024 & 2030
CHINA
Anti-Obesity Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 14: China Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 15: China 7-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2024 & 2030
EUROPE
Anti-Obesity Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 16: Europe Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 17: Europe 7-Year Perspective for Anti-Obesity Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
TABLE 18: Europe Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 19: Europe 7-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2024 & 2030
FRANCE
Anti-Obesity Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 20: France Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 21: France 7-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2024 & 2030
GERMANY
Anti-Obesity Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 22: Germany Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 23: Germany 7-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2024 & 2030
ITALY
TABLE 24: Italy Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 25: Italy 7-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2024 & 2030
UNITED KINGDOM
Anti-Obesity Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 26: UK Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 27: UK 7-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2024 & 2030
REST OF EUROPE
TABLE 28: Rest of Europe Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 29: Rest of Europe 7-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2024 & 2030
ASIA-PACIFIC
Anti-Obesity Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 30: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 31: Asia-Pacific 7-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2024 & 2030
REST OF WORLD
TABLE 32: Rest of World Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Type - Prescription Drugs and OTC Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 33: Rest of World 7-Year Perspective for Anti-Obesity Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and OTC Drugs for the Years 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings